168 related articles for article (PubMed ID: 17942351)
21. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
22. Unfractionated heparin promotes LPS-induced endothelial barrier dysfunction: a preliminary study on the roles of angiopoietin/Tie2 axis.
Li X; Zheng Z; Mao Y; Ma X
Thromb Res; 2012 May; 129(5):e223-8. PubMed ID: 22455983
[TBL] [Abstract][Full Text] [Related]
23. Oxidative stress induces myeloperoxidase expression in endocardial endothelial cells from patients with chronic heart failure.
La Rocca G; Di Stefano A; Eleuteri E; Anzalone R; Magno F; Corrao S; Loria T; Martorana A; Di Gangi C; Colombo M; Sansone F; Patanè F; Farina F; Rinaldi M; Cappello F; Giannuzzi P; Zummo G
Basic Res Cardiol; 2009 May; 104(3):307-20. PubMed ID: 19030913
[TBL] [Abstract][Full Text] [Related]
24. The influence of unfractionated and low-molecular weight heparins on the properties of human umbilical vein endothelial cells (HUVEC).
Gasowska K; Naumnik B; Klejna K; Myśliwiec M
Folia Histochem Cytobiol; 2009; 47(1):17-23. PubMed ID: 19419932
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of heparin induced anti-cancer activity in experimental cancer models.
Niers TM; Klerk CP; DiNisio M; Van Noorden CJ; Büller HR; Reitsma PH; Richel DJ
Crit Rev Oncol Hematol; 2007 Mar; 61(3):195-207. PubMed ID: 17074500
[TBL] [Abstract][Full Text] [Related]
26. High and low molecular weight heparins do not modify red blood cell aggregability in vitro.
Martínez M; Vaya A; López-Camacho C; Coll-Sangrona E; Mira Y; Aznar J
Clin Hemorheol Microcirc; 2000; 23(1):67-70. PubMed ID: 11214715
[TBL] [Abstract][Full Text] [Related]
27. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
28. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence.
Mousa SA; Petersen LJ
Thromb Haemost; 2009 Aug; 102(2):258-67. PubMed ID: 19652876
[TBL] [Abstract][Full Text] [Related]
29. Measurement of equine myeloperoxidase (MPO) activity in synovial fluid by a modified MPO assay and evaluation of joint diseases - an initial case study.
Fietz S; Bondzio A; Moschos A; Hertsch B; Einspanier R
Res Vet Sci; 2008 Jun; 84(3):347-53. PubMed ID: 17675122
[TBL] [Abstract][Full Text] [Related]
30. Effects of bemiparin, dalteparin, and unfractionated heparin on platelet interaction with human subendothelium under flow conditions.
González-Correa JA; Arrebola MM; Mérida F; Navas MD; López-Villodres JA; Samanes F; Cruz JP
J Pharmacol Sci; 2008 May; 107(1):103-6. PubMed ID: 18490857
[TBL] [Abstract][Full Text] [Related]
31. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
[TBL] [Abstract][Full Text] [Related]
32. Modulatory activities of Agelanthus dodoneifolius (Loranthaceae) extracts on stimulated equine neutrophils and myeloperoxidase activity.
Boly R; Dessy S; Kohnen S; Kini F; Lompo M; Mouithys-Mickalad A; Guissou IP; Dubois J; Deby-Dupont G; Serteyn D; Franck T
Int J Mol Med; 2011 Aug; 28(2):261-70. PubMed ID: 21573487
[TBL] [Abstract][Full Text] [Related]
33. Non-anticoagulant effects of unfractionated and low-molecular weight heparins.
Walenga JM
Clin Adv Hematol Oncol; 2007 Oct; 5(10):759-60. PubMed ID: 17998892
[No Abstract] [Full Text] [Related]
34. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
[TBL] [Abstract][Full Text] [Related]
35. Leukocyte-derived and endogenous matrix metalloproteinases in the lamellae of horses with naturally acquired and experimentally induced laminitis.
Loftus JP; Johnson PJ; Belknap JK; Pettigrew A; Black SJ
Vet Immunol Immunopathol; 2009 Jun; 129(3-4):221-30. PubMed ID: 19101039
[TBL] [Abstract][Full Text] [Related]
36. Oral heparins.
Hiebert LM
Clin Lab; 2002; 48(3-4):111-6. PubMed ID: 11934211
[TBL] [Abstract][Full Text] [Related]
37. Dynamic changes in circulating leukocytes during the induction of equine laminitis with black walnut extract.
Hurley DJ; Parks RJ; Reber AJ; Donovan DC; Okinaga T; Vandenplas ML; Peroni JF; Moore JN
Vet Immunol Immunopathol; 2006 Apr; 110(3-4):195-206. PubMed ID: 16290066
[TBL] [Abstract][Full Text] [Related]
38. Competitive inhibition of myosin ATPase activity by different molecular weight heparins.
Volpi N; Bianchini P; Bolognani L
Biochem Int; 1991 May; 24(2):243-53. PubMed ID: 1656981
[TBL] [Abstract][Full Text] [Related]
39. Equine laminitis: membrane type matrix metalloproteinase-1 (MMP-14) is involved in acute phase onset.
Kyaw-Tanner MT; Wattle O; van Eps AW; Pollitt CC
Equine Vet J; 2008 Jul; 40(5):482-7. PubMed ID: 18178538
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
Fiore MM; Mackie IM
Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
